Helen Torley

HALO CEO Helen Torley sells 50,000 shares for $3.4M under pre-arranged 10b5-1 plan on 2026-06-01/03

Helen Torley (President and CEO) executed 9 separate sales totaling 50,000 shares for $3,370,008.22 across three trading days (June 1–3, 2026) at an average price of $67.40 per share. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, meaning it was scheduled and not a discretionary decision by the executive. Post-transaction, Torley retains 767,780 non-derivative shares along with derivative holdings of 45,769 option shares, reducing her non-derivative position by 6.1%. The sale follows a pattern of recurring sales; Torley has sold at this ticker on five prior occasions (2026-05-12 and 2026-05-13), all of which showed negative 30- and 90-day returns ranging from -2.7% to -7.1%. Her cross-ticker track record of 20 prior sells shows an average 90-day return of -2.1%, suggesting her sales have historically preceded modest price declines. With HALO trading at $69.82 and the company reporting strong fundamentals—$376.7M in quarterly revenue, $150.0M net income, and 37.6% annual revenue growth—the scheduled nature of this sale limits its interpretive value as a discretionary signal.

CEO Helen Torley exercised options and immediately sold all gains, offsetting 50K shares acquired with 50K disposed—a neutral stake pattern that masks heavy profit-taking.

Helen Torley, President and CEO of HaloZyme, executed a high-volume trading sequence over three days: exercising 50,000 shares at a fixed price and simultaneously selling the same number of shares across twelve separate transactions at prices ranging significantly higher. This is a mechanically neutral net position—her direct stake remained essentially flat at 767,780 shares—but the transaction pattern itself reveals important context. Torley is a serial seller with 104 open-market sales across all her holdings in the trailing 36 months (12 at HaloZyme in this filing alone), and her five prior HaloZyme sales showed mixed timing: three were well-timed exits where the stock subsequently fell, but two were poorly timed as the stock rallied afterward. Over the longer 90-day horizon, all five prior HaloZyme exits proved poorly timed, as the stock gained in every instance. The current exercise-and-sell pattern happens while the stock trades well below its 52-week high and the company shows strong fundamentals—profitable with accelerating revenue growth and a reasonable valuation multiple. Torley's willingness to immediately liquidate every exercised share, combined with her exclusively sell-focused filing history and the mixed historical accuracy of her HaloZyme exits, does not convey insider conviction in the stock's near-term trajectory.

CEO Torley Helen sells 10,000 HALO shares across 2 trades for $634,981.60 ($63.50 avg); stock down 21.7% from 52-week high.

Torley Helen, President and CEO, executed 2 separate sales on 2026-04-06, totaling 10,000 shares for $634,981.60 at a blended average price of $63.50. The sale reduced her holdings from 777.8K to 767.8K shares (-1.3%). The current price is $63.60, slightly above the transaction price, and the stock is -21.7% from its 52-week high of $81.23, down 5.6% over 30 days and 15.3% over 90 days. The company shows strong fundamentals—annual revenue growth of +37.6%, a P/E of 16.02, and net income of $175.2M—which does not signal operational distress. Notably, Helen has executed 4 prior sales at HALO in the preceding five days (2026-04-01 and 2026-04-02), with the most recent measurable outcome (2026-03-04 sale) showing -9.1% return at 30 days. The pattern of frequent consecutive sales warrants examination against any scheduled plan or non-discretionary context; without explicit disclosure, the rapid cadence and recent price weakness merit investor attention.

HALO CEO Torley Helen sells 40,000 shares for $2.6M under pre-arranged 10b5-1 plan (adopted 2025-03-21)

Helen Torley, President and CEO of HaloZyme, executed 4 separate sales totaling 40,000 shares for $2,592,236.80 at a blended average price of $64.81 across April 1-2, 2026. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, meaning the sales were scheduled and not discretionary. Post-transaction, Torley retains 767,780 shares, representing a 5.0% reduction from prior holdings of 807,780 shares. The scheduled nature of this transaction precludes any inference about current conviction or market timing—10b5-1 plans are established on fixed schedules and executed mechanically regardless of near-term price movement.

CEO Helen Torley sold 50,000 shares ($3.5M) across 7 transactions Mar 2–4 at blended avg $69.52, reducing stake 6.1% to 767.8K shares post-sale.

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 7 separate open-market sales totaling 50,000 shares for $3,476,156.80 across March 2–4, 2026, at an average price of $69.52 per share. The sale reduces her holdings from 817.8K to 767.8K shares, a -6.1% reduction in position size. The current price of $70.02 sits -13.8% below the 52-week high of $81.23, and the stock has declined -6.0% over the prior 30 days while rising +11.2% over 90 days. Her cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 23.08% and an average 90-day return of +9.0%, suggesting her prior sells have not consistently preceded declines; notably, her five most recent trades at HALO itself (all sales between Feb 3–5, 2026) lack measurable 90-day outcomes. With the company reporting strong fundamentals—$354.3M quarterly revenue, $175.2M net income, and +37.6% annual revenue growth—and trading at a P/E of 17.64 against an $8.3B market cap, the sale occurs in a context of solid operational performance and recent valuation pullback, not operational distress.

HALO CEO Torley Helen sold 50,000 shares for $3.9M across 7 transactions (Feb 3–5); holds 708.7K shares post-sale.

Torley Helen, the President and CEO of HaLozyme, executed 7 separate sales totaling 50,000 shares for $3,853,503.25 between February 3 and 5, 2026, at prices ranging from $74.88 to $78.94 with a blended average of $77.07. The sale reduced her holdings by 6.6%, from 758.7K to 708.7K shares, while the stock currently trades at $78.42—just 1.9% above the execution prices. The timing context is noteworthy: across his cross-ticker track record of 20 prior sales, the average 90-day return has been -5.1% with a 90-day well-timed rate of 100%, but his 5 prior sales at HALO specifically (all in November and December 2025) showed mixed 30-day results (-1.8% to -11.4%) with no 90-day outcomes yet measurable. The company's fundamentals remain solid—annual revenue growth of +22.4%, a P/E of 15.50, and net income of $175,225,000.00 on quarterly revenue of $354,264,000.00—suggesting the sale reflects position management rather than company deterioration.

HALO CEO Torley Helen sold 16,569 shares for $1,141,924.75 on 2025-12-01 at blended avg $68.92

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 4 separate sales totaling 16,569 shares for $1,141,924.75 ($1.1M) on 2025-12-01, reducing holdings from 725,288 shares to 708,719 shares (-2.3%). The sales occurred at prices ranging from $68.51 to $71.60, with a blended average of $68.92, at a point when the stock was -13.0% from its 52-week high of $78.28 and trading at $68.10 currently (+4.5% over 30 days, -7.1% over 90 days). Across the insider's cross-ticker track record of 20 prior sells, the average 30-day return has been -9.2%, indicating a historical pattern of selling into periods of relative underperformance. HaloZyme's fundamentals remain solid with annual revenue growth of +22.4%, a P/E of 13.46, and recent quarterly revenue of $354.3M with net income of $175.2M, providing context that this sale occurs within a company showing strong financial performance.

HALO CEO Torley Helen sold 60,000 shares for $4.2M across Nov 10-12; part of pre-arranged 10b5-1 plan adopted Mar 21.

Torley Helen, HALO's President and CEO, executed 8 separate sales totaling 60,000 shares for $4,167,929.57 at a blended average price of $69.47 per share across three trading days (November 10–12, 2025). This reduction represents a 7.6% decrease in her pre-transaction holdings of 793.7K shares, leaving her with 733.7K shares post-transaction. Critically, this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, meaning the sales were scheduled in advance rather than discretionary decisions made in response to current market conditions. The multi-day execution across a price range of $67.89 to $71.67 reflects the systematic nature of the plan's schedule, not active trading judgment on her part.

CEO Torley Helen sells 60,000 HALO shares across 11 transactions for $4.3M at blended avg $71.86

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 11 separate sales totaling 60,000 shares for $4,311,745.13 on 2025-10-01 through 2025-10-03, reducing her holdings by 7.6% from 793.7K to 733.7K shares. The blended average sale price of $71.86 sits 4.2% above the current price of $68.98, indicating the sales occurred at a near-recent high despite the stock being 11.9% down from its 52-week high of $78.28. HaloZyme's fundamentals remain solid with annual revenue growth of +22.4%, net income of $165.2M on quarterly revenue of $325.7M, and a P/E of 14.49, suggesting the company is operationally sound. However, the magnitude of the CEO's disposal—$4.3M in concentrated selling across just three trading days—warrants observation, particularly given the recent 30-day and 90-day price weakness (-7.8% and +27.7% respectively) and prior same-ticker sales in early September that showed negative 30-day returns of -7.1% and -7.6%.

HALO CEO Torley Helen sold 60,000 shares for $4.4M in 8 transactions (Sept 2-4) via scheduled 10b5-1 plan

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 8 separate sales totaling 60,000 shares for $4,444,626.28 across September 2–4, 2025, at prices ranging from $72.48 to $75.22. This sale was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, making it a scheduled, non-discretionary transaction. The CEO's post-transaction holdings of 733,719 shares represent a 7.6% reduction from pre-transaction levels of 793,719 shares, though she retains substantial equity ownership in the company. As a scheduled plan execution, this transaction reflects predetermined trading activity rather than real-time market decision-making.